The Week

Constellation Brands (STZ) fell 4.47% this week to close at $122.45, while the S&P 500 lost 0.8%, leaving the stock about 3.67 percentage points behind the benchmark. The four sessions showed a sharp intraday reversal on Tuesday 8 September, with the stock spiking to $130.99 before sliding to a low of $120.43 and closing at $120.98. It then hit a 52-week low of $120.25 on Wednesday 9 September, bounced modestly over the next two days, and closed Friday at $122.45. The weekly range was 8.39%, with average daily volume around 2.87m shares, about 42.7% above the recent median.

Key Events

The week was shaped by debt moves and margin guidance. On Tuesday 8 September, the company said it had delivered a notice of redemption for its 4.350% senior notes due 2027. At the Barclays conference the same day, a company executive flagged some gross profit margin pressure in the second half of the year. The stock hit a 52-week low on Tuesday and Wednesday, prompting market discussion of whether it had fallen far enough to look undervalued. On 9 September the US banned imports of Canadian alcohol and dairy products, putting the US alcohol major on watch lists. Constellation also confirmed it will report second-quarter fiscal 2027 results after market close on 6 October, with a call at 8:00 am ET on 7 October.

Analyst Ratings

As of 11 September, 25 institutions cover STZ: 11 rate it buy, 3 overweight, 8 hold, 2 underweight, none sell, and 1 has no opinion. The consensus rating is buy. The consensus target of $170.22 sits about 39.0% above the spot price of $122.45. Targets range from $115 to $209, a wide spread. Among 10 peers in the alcoholic beverages industry, STZ ranks first in institutional coverage.

The Week Ahead

The key date is 6 October, when Constellation reports second-quarter fiscal 2027 results after the close; consensus estimates are EPS of $3.5514 and revenue of $2.55bn. Before that, next Tuesday brings the New York Fed Empire State manufacturing index, and Wednesday’s retail sales figures (prior 5.01, forecast 0.9) and import price index will add context on US consumption and cost pressures. A further thread is whether the stock can hold the $120 area after this week’s 52-week low.

In Short

The stock’s decline this week coincided with margin guidance, the redemption notice and the US ban on Canadian alcohol imports, but the causal links are unclear. The analyst picture leans constructive: most brokers rate it buy or overweight, and the consensus target sits about 39% above the current price, with top industry coverage. On the other side, the stock trades at roughly 11.5x P/E and 2.5x P/B, and the latest session showed small and medium lots as net sellers. The next test is whether October results validate the margin concerns and whether the stock can stabilise in the $120 to $122 zone.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.